United States Genetic Testing Market Outlook to 2021

Scope

- Genetic Testing market includes Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests.
- Annualized market revenues (USD million) data for each of the market categories. Data is provided from 2007 to 2014 and forecast to 2021.
- 2014 company shares and distribution shares data for Genetic Testing market.
- Global corporate-level profiles of key companies operating within the United States Genetic Testing market.
- Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Danaher Corporation, Abbott Laboratories, Hologic, Inc., Cepheid, Bio-Rad Laboratories, Inc., Qiagen N.V., Transgenomic, Inc. and PerkinElmer, Inc.

Table Of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 5
1.2 List of Figures 6
2 Introduction 7
2.1 What Is This Report About? 7
2.2 Genetic Testing Market Segmentation 7
2.3 Definitions of Markets Covered in the Report 8
3 Genetic Testing Market, United States 9
3.1 Genetic Testing Market, United States, Revenue ($m), 2007-2014 9
3.2 Genetic Testing Market, United States, Revenue ($m), 2014-2021 11
3.3 Genetic Testing Market, United States, Distribution Share by Revenue ($m), 2013-2014 13
3.4 Genetic Testing Market, United States, Company Share by Revenue ($m), 2014 14
4 Overview of Key Companies in United States, Genetic Testing Market 16
4.1 F. Hoffmann-La Roche Ltd. 16
4.1.1 Company Overview 16
4.2 Siemens Healthcare 16
4.2.1 Company Overview 16
4.3 Abbott Laboratories 16
4.3.1 Company Overview 16
4.4 Danaher Corporation 17
4.4.1 Company Overview 17
4.5 Hologic, Inc. 17
4.5.1 Company Overview 17
4.6 Cepheid 17
4.6.1 Company Overview 17
4.7 Bio-Rad Laboratories, Inc. 18
4.7.1 Company Overview 18
4.8 Qiagen N.V. 18
4.8.1 Company Overview 18
4.9 Transgenomic, Inc. 18
4.9.1 Company Overview 18
4.10 PerkinElmer, Inc. 19
4.10.1 Company Overview 19
5 Genetic Testing Market Pipeline Products 20
6 Financial Deals Landscape 24
6.1 Acquisition 24
6.1.1 Quest Diagnostics May Sell itself 24
6.1.2 Amarantus BioScience Acquires DioGenix 25
6.1.3 Roche Acquires Bina Technologies 26
6.1.4 IBM Watson Invests in Pathway Genomics 27
6.1.5 PDI Acquires RedPath Integrated Pathology for USD23 Million 28
6.1.6 Veracyte Acquires Allegro Diagnostics for USD21 Million 30
6.2 Asset Transactions 31
6.2.1 Pacific Biosciences of California Acquires PacBio Technology from BGI 31
6.2.2 Sequenom Acquires Noninvasive Prenatal Testing Intellectual Property from Isis Innovation for USD14.5 Million 32
6.3 Debt Offerings 34
6.3.1 Thermo Fisher Scientific Raises USD549.4 Million in Public Offering of 2.15% Notes Due 2022 34
6.3.2 LabCorp Raises USD500 Million in Public Offering of 2.625% Notes Due 2020 36
6.3.3 LabCorp Raises USD500 Million in Public Offering of 3.2% Notes Due 2022 38
6.3.4 LabCorp Raises USD1 Billion in Public Offering of 3.6% Notes Due 2025 40
6.3.5 LabCorp Raises USD900 Million in Public Offering of 4.7% Notes Due 2045 42
6.3.6 Thermo Fisher Scientific Raises USD801 Million in Public Offering of 2% Notes Due 2025 44
6.3.7 Thermo Fisher Scientific Raises USD800 Million in Public Offering of 3.3% Notes Due 2022 46
6.4 Equity Offerings 48
6.4.1 Trovagene Raises USD40.3 Million in Public Offering of Shares 48
6.4.2 Nanosphere to Raise USD4.4 Million in Private Placement of Convertible Preferred Stock 50
6.4.3 Nanosphere Raises USD4.4 Million in Private Placement of Series A Convertible Preferred Stock 51
6.4.4 Transgenomic Raises USD7 Million in Public Offering of Shares and Warrants 52
6.4.5 CombiMatrix to Raise USD3 Million in Private Placement of Warrants 54
6.4.6 CombiMatrix to Raise USD5 Million in Private Placement of Securities 56
6.4.7 Invitae Raises USD117 Million in IPO 58
6.4.8 AutoGenomics Withdraws IPO for up to USD48.7 Million 60
6.4.9 Interleukin Genetics Raises USD5 Million in Private Placement of Shares and Warrants 62
6.4.10 Exact Sciences Prices Public Offering of Shares for USD103 Million 64
6.4.11 Affymetrix to Raise USD50 Million in Private Placement of Shares 66
6.4.12 Nanosphere Terminates Private Placement of Shares for USD30 Million 67
6.4.13 Nanosphere Raises USD20 Million in Public Offering of Shares 68
6.4.14 DermTech Withdraws IPO 69
6.5 Partnerships 70
6.5.1 XIFIN Enters into Agreement with Translational Software 70
6.5.2 Cytox Enters into Joint Development Partnership with Affymetrix 71
6.5.3 Interleukin Genetics Enters into Licensing Agreement with NYU School of Medicine 72
6.5.4 Boston IVF Enters into Agreement with IviGen and iGenomix 73
6.5.5 Seattle Children's Hospital Enters into Agreement with NextGxDx 74
6.5.6 Genewiz Forms Joint Venture with Hy Labs 75
6.5.7 Biosearch Enters into Licensing Agreement with Co-Diagnostics 76
6.5.8 Merck Serono Enters into Co- Development Agreement with Illumina 77
6.5.9 WaferGen Biosystems Enters into Research Agreement with Women's College Research Institute 78
6.5.10 Genomic Vision Extends Agreement with Quest Diagnostics 79
6.5.11 Cypher Genomics Enters into Agreement with Sequenom to Develop Next Generation Noninvasive Prenatal Tests 80
6.5.12 Victorian Clinical Genetics Enters into Agreement with Illumina to Develop NIPT 81
6.5.13 Rosetta Genomics Enters into Co-Marketing Agreement with Admera Health 82
6.5.14 Foundation Medicine Enters into Licensing Agreement with WuXi PharmaTech 83
6.5.15 Affymetrix Enters into Licensing Agreement with Peptide Groove 84
6.5.16 Reprogenetics Enters into R&D Agreement with Illumina for Next-Generation In-Vitro Fertilization Sequencing Systems 85
6.5.17 NanoString Enters into Research Agreement with Brigham and Women’s Hospital 86
6.5.18 Advanced Biological Labs Enters into Licensing Agreement with Mayo Medical Labs 87
6.5.19 Lucigen Enters into Agreement with Thermo Fisher Scientific 88
6.5.20 New England Biolabs Enters into Licensing Agreement with Genomic Health for Ribosomal RNA Depletion Technology 89
6.5.21 Hibergene Diagnostics Enters into Licensing Agreement with Eiken for LAMP 90
6.5.22 WaferGen Biosystems Enters into Co-Development Agreement with Molecular Pathology Labs 91
6.6 Venture Financing 92
6.6.1 Rubicon Genomics Raises USD2 Million in Venture Financing 92
6.6.2 Courtagen Life Sciences Raises USD20 Million in Venture Financing 93
6.6.3 Personal Genome Diagnostics Raises USD4.3 Million in Venture Financing 95
6.6.4 Color Genomics Raises USD15 Million in Series A Financing 96
6.6.5 DxTerity Diagnostics Secures USD7.5 Million in Venture Debt Financing 97
6.6.6 DermTech Raises USD2.4 Million in Venture Financing 98
6.6.7 Claritas Genomics Raises USD15 Million in Series B Financing 99
6.6.8 Personalis Raises USD33 Million in Series C Financing 101
6.6.9 CardioDx Raises USD14 Million in Extended Series DD Venture Financing 102
6.6.10 KEW Group Raises USD16.8 Million in Venture Financing 103
6.6.11 InVitae Raises USD120 Million in Series F Venture Financing 104
6.6.12 IntegenX Secures USD10 Million in Financing 106
7 Appendix 107
7.1 Research Methodology 108
7.1.1 Coverage 108
7.1.2 Secondary Research 108
7.1.3 Primary Research 108
7.1.4 Company Share Analysis 109
7.1.5 Distribution Share Analysis 109
7.2 GlobalData Consulting 109
7.3 Contact Us 109
7.4 Disclaimer 110